Psivida wins technology award
15 July, 2004 by Melissa TrudingerNanotechnology company Psivida (ASX: PSD) has had its research applying its BioSilicon technology to drug delivery, diagnostics, orthopaedics and tissue engineering recognised with a 2004 Excellence in Research Award from US consulting group Frost & Sullivan.
Four of the best: pSiVida, Progen, AustCancer, Anadis
08 July, 2004 by Graeme O'NeillThree Australian biotechnology companies logged share price gains of over 300 per cent this financial year: pSivida (ASX: PSD) soared 387 per cent, Progen (ASX:PGL) was up 368 per cent and Australian Cancer Technology (ASX:ACU) was up 316 per cent. Biopharmaceutical company Anadis (ASX:ANX) also hit its stride, its share price rising 177 per cent.
Size isn't everything in nanotechnology
08 July, 2004 by Melissa TrudingerNanobiotechnology is one of the main opportunities for Australia to develop capabilities in nanotechnology, the CEO of Nanotechnology Victoria (Nanovic) Peter Binks said today.
Schofield leaves Garvan to join Prince of Wales
07 July, 2004 by Renate KrelleNeuroscience and mental illness specialist Prof Peter Schofield has been appointed executive director and CEO of the Prince of Wales Medical Research Institute, and plans to move his 15-strong research team from the Garvan Institute to yet-to-be-built labs in Sydney’s Randwick.
IDT scores Pfizer contract
05 July, 2004 by Melissa TrudingerThe Institute of Drug Technology (ASX: IDT) has scored a multi-million dollar contract with Pfizer to develop and manufacture a new drug candidate.
Scottish biotech Cyclacel joins IPO bandwagon
05 July, 2004 by Staff WritersScottish cancer specialist Cyclacel has announced plans to float on Nasdaq and the London Stock Exchange.
LEK's McIntyre joins BioTech Capital board
01 July, 2004 by Iain ScottDr Lisa McIntyre, the head of LEK Consulting's Asia-Pacific life sciences practice, has joined the board of Sydney-based pooled development fund BioTech Capital (ASX:BTC).
NSW, feds to fund Sydney medical research complex
30 June, 2004 by Renate KrelleSydney's Victor Chang Cardiac Research Institute will get new digs, the Garvan Institute will get its building back, and both will be sharing café and confocal microscopy facilities with researchers from over the road at St Vincent's Hospital, if a $46 million new laboratory building gets underway.
From grapes to grants: new ARC head outlines plans
30 June, 2004 by Susan WilliamsonProf Peter Høj, currently director of the Australian Wine Research Institute, has been appointed the new CEO of the Australian Research Council (ARC).
Mind your fingers as the IPO window closes
29 June, 2004 by Renate KrelleMarket analysts are wondering whether the windown for Australian biotech IPOs has slammed shut.
UNSW spin-out Acyte collaborates with Serono
22 June, 2004 by Renate KrelleAcyte Biotechnology, a spin-out from the University of New South Wales, is to team up with Swiss biopharmaceutical giant Serono to develop recombinant proteins using Acyte's mammalian cell expression technology.
How Myriad's GCAT got out of the bag
21 June, 2004 by Graeme O'NeillThe past two decades have produced a plethora of patents for DNA diagnostic tests to determine people's susceptibility to common, life-threatening disorders like cancer, cardiovascular disease, hypertension and neurodegenerative diseases like Alzheimer's disease and motor neuron disease.
What not to do: the top 10 patenting mistakes
21 June, 2004 by Renate KrelleYou've run your experiments, got your results, and you've been mentally spending -- or at least licensing -- the proceeds of your bulging IP portfolio. But that may have been the easy part, writes Renate Krelle. Before you go any further, here's a checklist of some of the most common patenting pitfalls.
The end of the pioneer trail
21 June, 2004 by Melissa TrudingerAustralia's first ever Cooperative Research Centre is winding up operations. Melissa Trudinger joined its stakeholders for a look back at its successes.
COVER STORY: Lab to order
21 June, 2004 by Susan WilliamsonImagine if you could map out your dream lab on the concrete floor -- and then stock it with whatever you wanted. Susan Williamson spoke with Ian Findlay and his team at Gribbles Molecular Science, who did just that.
